A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DME / drug metabolizing enzymes

[Related PubMed/MEDLINE]
Total Number of Papers: 69
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DME  (>> Co-occurring Abbreviation)
Long Form:   drug metabolizing enzymes
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Modulation of aflatoxin B1 cytotoxicity and aflatoxin M1 synthesis by natural antioxidants in a bovine mammary epithelial cell line. AF
2019 Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes. DDI, PBPK, PK, QSAR
2018 A Novel In vitro Experimental System for the Evaluation of Enteric Drug Metabolism: Cofactor-Supplemented Permeabilized Cryopreserved Human Enterocytes (MetMax™ Cryopreserved Human Enterocytes). CCHE, CES2, MMHE, NAT-1, SULT, UGT
2018 Cancer Chemoprevention and Piperine: Molecular Mechanisms and Therapeutic Opportunities. CSC, MDR, P-gp
2018 Effects of renal impairment on transporter-mediated renal reabsorption of drugs and renal drug-drug interactions: A simulation-based study. GHB, PMID, RI
2018 Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes. AhR, CAR, DDIs, NRs, PXR, UGT
2018 Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals. CDNB, GSTs, NQO1, NQO2, SULTs, UGTs
2018 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. miRNA
2018 Whole-cell-dependent biosynthesis of sulfo-conjugate using human sulfotransferase expressing budding yeast. SULTs
10  2017 Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). VLX
11  2016 Classification of Human Pregnane X Receptor (hPXR) Activators and Non-Activators by Machine Learning Techniques: A Multifaceted Approach. DDI, ET, hPXR, k-NN, MDR, NB, RF, SVM
12  2016 Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients. GMDR, GMDR
13  2016 Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells. CYP2C19, NXT, PXR, qPCR
14  2016 Upcyte Human Hepatocytes: a Potent In Vitro Tool for the Prediction of Hepatic Clearance of Metabolically Stable Compounds. CL, PHH, UHH
15  2015 An enhanced in vivo stable isotope labeling by amino acids in cell culture (SILAC) model for quantification of drug metabolism enzymes. CES, Gst, HSD, SILAC
16  2015 An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. EFV, HAART, SNPs
17  2015 Dietary Doses of Sulforaphane Affect Hepatic Drug Metabolizing Enzymes in Spontaneously Hypertensive Rats. mEH, SF, SHR
18  2015 Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs. ---
19  2015 Drug-metabolizing and antioxidant enzymes in monosodium L-glutamate obese mice. GST, NQO1, Nrf2, UGT1A
20  2015 Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro. EEDS, p-gp
21  2015 Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer. ---
22  2015 Pharmacokinetics and pharmacodynamics of 3,3'-diindolylmethane (DIM) in regulating gene expression of phase II drug metabolizing enzymes. DIM, i.v, PD, PK
23  2014 A targeted in vivo SILAC approach for quantification of drug metabolism enzymes: regulation by the constitutive androstane receptor. CAR
24  2014 Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. ---
25  2014 Effect of commercially available green and black tea beverages on drug-metabolizing enzymes and oxidative stress in Wistar rats. BT, GT
26  2014 Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice. BA, IFN-gamma, IL-6, TLR4
27  2014 The role of drug metabolizing enzymes in clearance. ---
28  2014 Toxicogenetic profile and cancer risk in Lebanese. CYP, GST, NAT
29  2013 Pharmacogenetics and personalized treatment of type 2 diabetes. DT, OAD, T2DM
30  2012 Genetic polymorphism of drug metabolizing enzymes in association with risk of bile duct cancer. CCA, GSTM1, MTHFR, NAT1, NQO1
31  2012 Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. ATLI, CIs, ORs
32  2012 Pharmacokinetics and pharmacodynamics of phase II drug metabolizing/antioxidant enzymes gene response by anticancer agent sulforaphane in rat lymphocytes. IDR, PD, PK, SFN
33  2012 PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. DBDs
34  2011 Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. CYP3A4, GCDCA, UGT2B4
35  2011 Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. ARE, DIM, I3C, ITCs, PEITC, qPCR, SFN
36  2011 The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes. CAR, CPA, HPH, IFO, PXR
37  2011 Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability. EM, PCR-RFLP, PM
38  2010 Effects of hepatic drug-metabolizing enzyme induction on clinical pathology parameters in animals and man. ---
39  2010 Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. ---
40  2010 Introduction to hepatic drug metabolizing enzyme induction in drug safety evaluation studies. ---
41  2010 Species-specific activation of nuclear receptors correlates with the response of liver drug metabolizing enzymes to EMD 392949 in vitro. AhR, NXRs, P450s, PXR, XREM
42  2009 Regulation of drug metabolism and transporters. ---
43  2009 Symposium "Clinical Pharmacology Anno 2008". 10th Heymans Memorial Lecture. ---
44  2008 Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. ATLI, CYP2E1, GST, NAT2
45  2008 Regulation of hepatic drug-metabolizing enzyme genes by Toll-like receptor 4 signaling is independent of Toll-interleukin 1 receptor domain-containing adaptor protein. LPS, NRs, RXRalpha, TLR4
46  2008 The ontogeny of drug metabolism enzymes and implications for adverse drug events. ---
47  2008 Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. AhR, ARNT, GST, LXR, PBMC, PPAR, PXR, TF
48  2007 Application of pharmacogenomics in drug discovery and development: correlations between transcriptional modulation and preclinical safety observations. NSP
49  2007 Ontogeny of human hepatic cytochromes P450. ---
50  2005 Effect of breed and gender on bovine liver cytochrome P450 3A (CYP3A) expression and inter-species comparison with other domestic ruminants. CYP3A, LIM, PDM
51  2005 Medical devices; clinical chemistry and clinical toxicology devices; drug metabolizing enzyme genotyping system. Final rule. FDA
52  2005 Toxicogenomics of resveratrol in rat liver. CYP1A1, CYP2E1, GST, UGT
53  2005 Tumoral drug metabolism: overview and its implications for cancer therapy. ---
54  2005 [Cancer chemotherapy and drug metabolism enzyme]. DPD, GST, TPMT, UGT
55  2004 A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulators. ARE, EQ, SFP, XRE
56  2003 Tumoral drug metabolism: perspectives and therapeutic implications. ---
57  2002 Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. HCC, HCV, mEH, ORs, PCR, RFLPs
58  2002 [Drug-drug interaction in pharmacogenetics and pharmacogenomics]. AUC
59  2001 Population genetic structure of variable drug response. ---
60  2000 Amplifying effect of dietary taurine on the induction of cytochrome P-450 and on the urinary excretion of ascorbic acid in rats fed on phenobarbital-containing diets. PB
61  2000 Genetic polymorphism of CYP2A6 in the German population. ---
62  1999 Malnutrition sequela on the drug metabolizing enzymes in male Holtzman rats. AHH, CO, EORD, GST, MO, NDMAd, RF
63  1999 Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? ---
64  1996 Effect of hexavalent chromium on drug-metabolizing enzymes in male domesticated rabbits. DAO, PB, PM
65  1994 Effects of phenobarbital on drug metabolizing enzyme activities and other biochemical parameters in rats with DL-ethionine-induced liver injury. AMD, ANH, ET, LDH, PB
66  1993 Effects of caloric restriction on rodent drug and carcinogen metabolizing enzymes: implications for mutagenesis and cancer. CYP2C11
67  1990 Maturational development of drug-metabolizing enzymes in dogs. ---
68  1990 Maturational development of drug-metabolizing enzymes in sheep. ---
69  1984 Dose related induction of the drug metabolizing enzymes of rat liver by cilobamine. PB